Medical Device Classification: How 15 Markets Compare
Here's a fact that surprises many first-time exporters: the same medical device can have different risk classifications in different countries. A Class II device in the US might be Class IIb in the EU and Class C in Singapore. The rules aren't the same, the class labels aren't the same, and the regulatory consequences are very different.
Understanding these differences isn't academic — it directly impacts your market entry strategy, timeline, and budget.
The Classification Systems at a Glance
Systems Based on GHTF/IMDRF Framework
These countries use a 4-tier system (A/B/C/D or equivalent), based on the Global Harmonization Task Force framework:
| Market | Classes | Authority | Based On |
|---|---|---|---|
| Singapore | A, B, C, D | HSA | GHTF |
| Australia | I, IIa, IIb, III | TGA | GHTF + EU-aligned |
| Canada | I, II, III, IV | Health Canada | GHTF |
| Malaysia | A, B, C, D | MDA | ASEAN/GHTF |
| Thailand | 1, 2, 3, 4 | Thai FDA | ASEAN/GHTF |
| Philippines | A, B, C, D | FDA Philippines | ASEAN/GHTF |
| Vietnam | A, B, C, D | MOH | ASEAN/GHTF |
| Indonesia | A, B, C, D | BPOM | ASEAN/GHTF |
EU-Style Systems
| Market | Classes | Authority | Based On |
|---|---|---|---|
| EU | I, IIa, IIb, III | Notified Bodies / Competent Authorities | EU MDR 2017/745 |
| South Korea | 1, 2, 3, 4 | MFDS | EU MDD-inspired |
Unique Systems
| Market | Classes | Authority | Notes |
|---|---|---|---|
| US | I, II, III | FDA | Product code–based, predicate system |
| Japan | I, II, III, IV | PMDA/MHLW | Unique classification lists |
| China | I, II, III | NMPA | Product catalog–based |
| India | A, B, C, D | CDSCO | GHTF-based but with local rules |
| Hong Kong | N/A | MDCO | No classification system — reliance only |
Why the Same Device Gets Different Classes
Example: Infusion Pump
| Market | Class | Why |
|---|---|---|
| US (FDA) | Class II | Well-established technology, 510(k) predicates available |
| EU (MDR) | Class IIb | Active therapeutic device delivering substances in potentially hazardous manner (Rule 12) |
| Singapore (HSA) | Class C | Moderate-high risk, active device |
| Japan (PMDA) | Class III | Specifically classified in PMDA device classification list |
| China (NMPA) | Class III | Listed as Class III in Chinese device catalog |
Same device. Five different regulatory experiences.
Example: Blood Glucose Meter
| Market | Class | Why |
|---|---|---|
| US (FDA) | Class II | 510(k) pathway, established technology |
| EU (MDR) | Class IIa | Self-testing IVD under IVDR |
| Singapore (HSA) | Class B | Low-moderate risk IVD |
| Japan (PMDA) | Class II | Standard classification |
| India (CDSCO) | Class B | Aligned with GHTF |
Example: AI Diagnostic Software
This is where things get interesting — and where classification diverges most dramatically:
| Market | Class | Why |
|---|---|---|
| US (FDA) | Class II | Most AI/ML devices cleared via 510(k) or De Novo |
| EU (MDR) | Class IIa–III | Rule 11 — depends on condition severity |
| Singapore (HSA) | Class B–D | Depends on clinical decision being supported |
| Japan (PMDA) | Class II–III | Case-by-case classification |
| China (NMPA) | Class II–III | Specific AI/ML guidance issued 2023 |
An AI tool that screens for diabetic retinopathy might be Class II in the US but Class III in the EU. That's a difference of 12+ months and hundreds of thousands of dollars.
Key Differences That Affect Strategy
1. Software / SaMD Classification
The biggest divergence across markets. EU MDR Rule 11 is notably aggressive — software intended to influence diagnostic or therapeutic decisions for serious conditions goes straight to Class III. FDA is generally more lenient, with most SaMD cleared as Class II.
Impact: SaMD companies should consider US-first strategies if EU classification pushes them to Class III.
2. Mutual Recognition and Reliance
Several markets offer faster pathways if you already have approval elsewhere:
- Singapore recognizes FDA, EU, TGA, Health Canada
- Australia recognizes EU CE marking for some classes
- ASEAN markets recognize each other through the AMDD framework
- Hong Kong is entirely reliance-based — no independent review
Impact: The order in which you enter markets matters enormously. Getting FDA or CE first can halve your timeline for subsequent markets.
3. Implantable Device Treatment
Almost universally high-risk, but the specific requirements vary:
- US: Class III → PMA (clinical trials typically required)
- EU: Class III → Notified body + clinical evaluation (may not require trial)
- Japan: Class IV → PMDA review (clinical data requirements vary)
- China: Class III → NMPA review + often requires local clinical trial
4. IVD vs. Medical Device Split
Some countries regulate IVDs under separate frameworks:
- EU: IVDR 2017/746 (separate from MDR)
- US: FDA regulates under same 510(k)/PMA framework
- China: Separate IVD registration pathway under NMPA
If your device has both diagnostic and therapeutic functions, check whether each market treats it as IVD, medical device, or combination.
Building a Multi-Market Strategy
The optimal market entry sequence depends on your device type, existing approvals, and commercial priorities. But some general principles:
- Start with markets that create leverage. FDA clearance or CE marking opens doors in 10+ other markets.
- Group ASEAN together. If entering any ASEAN market, prepare the CSDT format — it's reusable across all member states.
- Plan for China and Japan separately. Both have unique requirements (local clinical trials, local testing) that don't benefit from other approvals.
- Consider Hong Kong as a quick win. Reliance-based system means minimal additional work if you have an existing approval.
- Don't underestimate India. CDSCO has become significantly more structured, and the market is massive.
Classify Across All 15 Markets Instantly
Manually researching classification rules across 15 markets takes weeks. regMD's free classification tool does it in seconds — enter your device description and get instant classification results across all markets.
For the complete multi-market regulatory strategy — including optimal entry sequence, timeline projections, cost estimates, and mutual recognition pathways — get lifetime access for $99.
This article is for informational purposes only and does not constitute regulatory advice. Classification rules change frequently — always verify with the relevant regulatory authority or a qualified consultant.